Tecentriq – media

First-line use of Roche’s Tecentriq given priority review

US regulators are undertaking a priority review of Roche unit Genentech’s PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer.
- Source: pharmatimes
- 629
- May 9, 2018
Chemotherapy lung cancer Roche Tecentriq
Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.
- Source: Biospace
- 662
- February 11, 2018
Clinical Trial inhibitor mRCC Tecentriq

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.